Arcellx (NASDAQ:ACLX) Cut to Equal Weight at Wells Fargo & Company

Wells Fargo & Company lowered shares of Arcellx (NASDAQ:ACLX) from an overweight rating to an equal weight rating in a research report report published on Monday morning, MarketBeat Ratings reports. They currently have $115.00 price target on the stock.

A number of other analysts have also recently issued reports on ACLX. UBS Group initiated coverage on Arcellx in a research note on Wednesday, January 7th. They set a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcellx in a research report on Wednesday, January 21st. Guggenheim reiterated a “buy” rating on shares of Arcellx in a report on Monday, November 24th. Rothschild & Co Redburn downgraded Arcellx from a “buy” rating to a “neutral” rating and set a $82.00 price target on the stock. in a research note on Thursday, February 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $105.00 price objective on shares of Arcellx in a research report on Thursday, February 5th. One research analyst has rated the stock with a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $111.87.

Arcellx Stock Performance

ACLX opened at $113.76 on Monday. The firm has a market cap of $6.58 billion, a PE ratio of -28.95 and a beta of 0.36. Arcellx has a twelve month low of $47.86 and a twelve month high of $114.26. The firm’s fifty day moving average is $69.82 and its two-hundred day moving average is $75.65.

Insider Activity

In other news, insider Christopher Heery sold 5,882 shares of the company’s stock in a transaction that occurred on Wednesday, January 14th. The stock was sold at an average price of $68.51, for a total transaction of $402,975.82. Following the sale, the insider owned 23,749 shares in the company, valued at $1,627,043.99. This represents a 19.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders sold 19,450 shares of company stock worth $1,283,477. Corporate insiders own 8.35% of the company’s stock.

Institutional Investors Weigh In On Arcellx

A number of institutional investors and hedge funds have recently modified their holdings of ACLX. T. Rowe Price Investment Management Inc. lifted its stake in Arcellx by 66.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,560,425 shares of the company’s stock valued at $688,540,000 after purchasing an additional 4,208,069 shares during the last quarter. Invesco Ltd. boosted its position in Arcellx by 19.9% during the fourth quarter. Invesco Ltd. now owns 40,372 shares of the company’s stock worth $2,632,000 after purchasing an additional 6,704 shares during the period. Mercer Global Advisors Inc. ADV raised its position in shares of Arcellx by 19.0% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 4,107 shares of the company’s stock valued at $268,000 after purchasing an additional 655 shares during the period. XTX Topco Ltd acquired a new position in Arcellx in the 4th quarter valued at about $4,732,000. Finally, Vestal Point Capital LP lifted its position in Arcellx by 134.0% during the fourth quarter. Vestal Point Capital LP now owns 2,925,000 shares of the company’s stock worth $190,710,000 after acquiring an additional 1,675,000 shares during the last quarter. 96.03% of the stock is owned by institutional investors.

More Arcellx News

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for up to $7.8 billion, a transformational M&A outcome that explains much of the upward price pressure by crystallizing acquisition value for ACLX shareholders. Gilead to buy Arcellx
• Neutral Sentiment: HC Wainwright published a FY2030 EPS projection (very bullish numerically) with a $115 price target but maintained a “Neutral” rating — the target is close to the current trade and offers limited additional upside. (Source: market research note)
• Neutral Sentiment: Short‑interest data reported for late February shows 0 shares and a 0.0 days‑to‑cover figure, which appears to be a data anomaly and therefore provides no clear signal about short‑seller pressure.
• Negative Sentiment: A broad set of sell‑side shops (Leerink, Evercore, Needham, Wells Fargo, Citigroup, Truist, Canaccord and others) moved ACLX toward “Hold” from stronger stances (strong‑buy/buy/outperform). Several firms cut or trimmed price targets (Truist cut to $120 from $134; others adjusted targets and ratings), creating short‑term headwinds and mixed sell signals despite the M&A news. Citigroup downgrades Arcellx Analyst coverage roundup

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.